Skip to main content

Advertisement

SpringerLink
Log in

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  2. Beer TM et al. (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 91: 1425–1427

    Article  CAS  Google Scholar 

  3. Joly F and Tannock IF (2004) Chemotherapy for patients with hormone refractory prostate cancer. Ann Oncol 15: 1582–1584

    Article  CAS  Google Scholar 

  4. Petrylak DP (2004) Treatment options for advanced and high-risk prostate cancer. In Proceedings of the Changing Paradigms in Prostate Cancer Symposium: 2004 October 9; London

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Head of the Department of Oncology at Assaf Harofeh Medical Center, Zerifin, Israel

    Avishay Sella

Authors
  1. Avishay Sella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avishay Sella.

Ethics declarations

Competing interests

The author has provided docetaxel for use in a neoadjuvant trial in localized prostate cancer with poor prognosis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sella, A. Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Urol 2, 18–19 (2005). https://doi.org/10.1038/ncpuro0064

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0064

  • Springer Nature Limited

Search

Navigation